BlackRock, Inc. 13D and 13G filings for Sage Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale |
2025-03-31 | 13G | Sage Therapeutics, Inc. SAGE |
BlackRock Inc. BLK |
4,425,077 7.200% |
-965,836 (-17.92%) |
Filing |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Sage Therapeutics, Inc. SAGE |
BlackRock Inc. BLK |
5,390,913 8.800% |
0 (Unchanged) |
Filing |
| 2024-10-21 4:11 pm Purchase |
2024-09-30 | 13G | Sage Therapeutics, Inc. SAGE |
BlackRock Inc. BLK |
5,390,913 8.800% |
727,013 (+15.59%) |
Filing |
| 2024-01-26 11:49 am Sale |
2023-12-31 | 13G | Sage Therapeutics, Inc. SAGE |
BlackRock Inc. BLK |
4,663,900 7.800% |
-246,242 (-5.01%) |
Filing |
| 2023-02-03 12:10 pm Purchase |
2022-12-31 | 13G | Sage Therapeutics, Inc. SAGE |
BlackRock Inc. BLK |
4,910,142 8.300% |
1,999,872 (+68.72%) |
Filing |
| 2021-01-08 4:37 pm Purchase |
2020-12-31 | 13G | Sage Therapeutics, Inc. SAGE |
BlackRock Inc. BLK |
2,910,270 4.990% |
125,022 (+4.49%) |
Filing |